The Patent Office, Government of India has approved two of the Company's patent applications. The now granted patent is a protection of the proprietary TSE technology, specifically, the creation of dynamic pulses, as well as the specialised probe and treatment kits, the protection extends to 2038.

It also marks a significant milestone in ChemoTech's mission to diversify cancer treatment, particularly in India, by enhancing the accessibility to our cutting-edge technology.

"The approval of these patent now gives us legal protection from any kind of attempt to infringement in India. As the sole provider of TSE technology in India, we are exempt from participating in public tenders, streamlining, and expediting the sales process significantly." said Mohan Frick, CEO of Scandinavian ChemoTech

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90

E-mail: certifiedadviser@redeye.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-04-2024 14:30 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.